Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023
"We are eagerly anticipating showcasing our MOPCTx platform at the
The MOPCTx platform, comprised of a modified mRNA encapsulated in a lipid nanoparticle, can code for a viral or bacterial antigen or a molecular adjuvant. The modifications enable targeted expression of these proteins in selected tissues, such as the site of injection. This leads to improved biodistribution over existing mRNA-based vaccine technologies while maintaining strong immunogenicity. Our platform reduces antigen protein expression ~90% or more in key vital organs such as the liver, kidneys, and heart while still maintaining expression at the site of injection. Our SARS-CoV-2 MOPCTx vaccine shows strong immunogenicity and protection in hamsters from COVID-19 challenge. Moreover, Combined Therapeutics' approach involves co-administering IL-12 mRNA with an antigen to enhance the immune system response, also known as molecular adjuvantation.
World Vaccine Congress brings together leading experts and researchers in the field of vaccines to share the latest scientific advancements and trends in the development of new vaccines and therapies.
The affiliations in the oral communication include
"We are thrilled to unveil the results of our collaborative efforts, leveraging the exceptional research capabilities of Combined Therapeutics, alongside the expertise of
Oral Communication Details:
Presenter: Dr.
Title: Adjuvanted mRNA Vaccines Targeted to Vulnerable Populations
Vaccine technology workshop, Breakthrough vaccine technologies
Session Date and Time: April 3,
Poster Presentation Details:
Presenter:
Title: MOPCTx: The next generation of mRNA-based vaccines to prevent infectious disease with improved biodistribution and long-lasting immunogenicity
Session Date and Time:
About Combined Therapeutics
Combined Therapeutics, making the world a better place. For all.
Combined Therapeutics is based in Boston and has international operations located in London and Paris. For more information, please visit the company's website at www.combinedtx.com. Follow the company on LinkedIn and Twitter.
Media Contact:
David Schull or Ignacio Guerrero-Ros, Ph.D.
+1 (858) 717-2310
+1 (646) 942-5604
[email protected]
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/combined-therapeutics-to-present-its-next-generation-mrna-based-vaccine-platform-at-the-world-vaccine-congress-2023-301785586.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AS Tallinna Vesi will hold an Investor Conference Webinar to introduce the results for the 1st quarter of 2024
- Nexstim Plc Business Update Q1 2024
- GXO helps Virgin Media O2 cut single use plastic
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!